Chronic hepatitis delta (CHD) affects millions worldwide with many undiagnosed. It requires the presence of hepatitis B virus (HBV) for viral propagation, and those who are coinfected have a more rapid development of cirrhosis, hepatocellular carcinoma and fulminant liver failure. Treatments licensed for HBV have been ineffective in those with CHD. As an orphan disease, there is only one licensed treatment for CHD in Europe, which has relatively limited efficacy and viral control. This review focuses on current treatments, recent advances and unresolved issues in hepatitis delta management.
No takes yet. Share an insight, caveat, or question.
Cargill et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: